Anzeige
Mehr »
Sonntag, 13.09.2026 - Börsentäglich über 12.000 News
Flucht aus dem Dollar? Gold explodiert - und hier wurden historische 80,4 g/t erbohrt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A422GY | ISIN: US72941H8060 | Ticker-Symbol: XMP1
Düsseldorf
11.09.26 | 19:30
2,020 Euro
-2,65 % -0,055
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENOME INC Chart 1 Jahr
5-Tage-Chart
CERENOME INC 5-Tage-Chart

Aktuelle News zur CERENOME Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCERENOME, INC. - 8-K, Current Report10
DoCerenome, Inc.: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment365Capital will support continued CNSide commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028...
► Artikel lesen
17.08.Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook22
CERENOME Aktie jetzt für 0€ handeln
14.08.Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update443HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics...
► Artikel lesen
13.08.Cerenome, Inc.: Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide Contracted Coverage to Over 150 Million Covered Lives23
06.08.Cerenome subsidiary selects XiFin for diagnostic billing services11
04.08.CERENOME, INC. - 8-K, Current Report32
03.08.Plus Therapeutics Rebrands with Launch of Cerenome2
31.07.Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company642HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective...
► Artikel lesen
21.07.CNSide Diagnostics signs coverage deal with Medical Mutual14
21.07.Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer411HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed...
► Artikel lesen
16.07.Plus Therapeutics partners with GTC on CSF diagnostic platform15
16.07.Plus Therapeutics Inc.: Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide CSF Assay Platform369HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration...
► Artikel lesen
14.07.Plus Therapeutics Inc.: Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring276HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network (NCCN)...
► Artikel lesen
01.07.Plus Therapeutics rebrands as Cerenome as it deepens AI strategy3
30.06.Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY3
30.06.Plus Therapeutics Inc.: Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding515Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide commercial progress HOUSTON, June 30...
► Artikel lesen
25.06.Plus Therapeutics wins Elevance Health coverage deal3
25.06.CNSide signs coverage deal with Elevance Health for 45.4M4
25.06.Plus Therapeutics Inc.: Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer4
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1